ClinicalTrials.gg
RecruitingNCT07220252Updated Oct 29, 2026

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

A Phase 2/3 interventional study of Ublituximab and Placebo in Relapsing Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Recruiting at 6 sites in 3 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by TG Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 29, 2026First sites in Slovakia and United States3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ublituximab in Multiple Sclerosis — 5 open to participants now, 7 under way, 4 of them phase 3. ublituximab · Multiple Sclerosis.

Planned enrollment
7th of 10
240 · median 355
Started
2026
with 2 others
Phase 2/3
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
8 of 10
TG Therapeutics, Inc.

Among the 10 studies testing ublituximab in Multiple Sclerosis, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 2/3, and was the 7th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 10 studies testing ublituximab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ublituximab in Multiple Sclerosis, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (\<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to less than or equal to (≤)40 kg with RMS (Part A) and to evaluate the non-inferiority of ublituximab compared with fingolimod in pediatric RMS participants with body weight ≥ 25 kg (Part B). The study will further evaluate long-term safety and efficacy of ublituximab in RMS in pediatric participants during its extension period (Part C).

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Part A and Part B:

  1. Diagnosis of RMS.
  2. EDSS at screening: 0-5.5, inclusive.
  3. Neurologic stability for ≥ 30 days prior to screening, and between screening and Week 1 Day 1 (W1D1).

Inclusion Criteria for Part C:

1. Participants must have completed Part A (Week 24 visit) or Part B (Week 96 visit) to be eligible for Part C.

Exclusion Criteria for Part A and B:

  1. Known presence or suspicion of other neurologic disorders that may mimic MS.
  2. Prior treatments:

    1. Systemic (>0.1 milligrams/kilogram/day [mg/kg/day], or >5 milligrams/day [mg/day] of prednisone equivalent) or adrenocorticotropic hormone (ACTH) within 30 days prior to the screening MRI scan (note: Topical, ophthalmic, or inhaled corticosteroids are permitted).
    2. High dose intravenous immunoglobulin (IVIG) or subcutaneous IG (SCIG) within 2 months prior to W1D1.
    3. Treatment with anti-CD20 or other B cell directed treatment at any time.
    4. Treatment with alemtuzumab, cladribine, cyclophosphamide, mitoxantrone at any time.

Additional Exclusion Criteria for Part B Only (Relevant to Fingolimod Treatment):

  1. Treatment with fingolimod or other sphingosine-1 phosphate-1 (S1P1) modulators at any time.
  2. The following antiarrhythmic drugs at Screening: Class Ia anti-arrhythmics.

Exclusion Criteria for Part C:

1. If the absolute lymphocyte count (ALC) is outside the specified range the participant will not be eligible to receive ublituximab in Part C.

Note: Other protocol-specified inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Part A: Ublituximab

    New Regimen

    Drug: Ublituximab

  • Experimental
    Part B: Ublituximab

    New Regimen

    Drug: Ublituximab

  • Placebo comparator
    Part B: Placebo

    Drug: Placebo

  • Experimental
    Part B: Fingolimod

    Drug: Fingolimod

  • Placebo comparator
    Part B: IV Placebo

    Drug: Placebo

  • Experimental
    Part C: OLE

    Drug: Ublituximab

Interventions

  • Administered as an intravenous (IV) infusion.

    Also known as: TG-1101, BRIUMVI

  • DrugPlacebo

    Oral capsule.

  • DrugPlacebo

    IV infusion.

  • Oral capsule.

06

What researchers measure

Primary outcomes

  1. Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab

    Time frame: Predose and multiple timepoints up to Week 24

  2. Part A: Maximum Observed Concentration (Cmax) of Ublituximab

    Time frame: Day 1 and Day 15

  3. Part A: Participant B Cell Counts

    Time frame: Up to Week 24

  4. Part B: Annualized Relapse Rate (ARR)

    Time frame: Up to 96 weeks

  5. Part C: Annualized Relapse Rate (ARR)

    Time frame: Up to 168 weeks

Secondary outcomes

  1. Part A, B and C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks; Part C: Up to 168 weeks

  2. Part A, B and C: Number of Participants With Change in Columbia-Suicide Severity Rating Scale (C-SSRS )

    Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks; Part C: Up to 168 weeks

  3. Part A: Serum Concentrations of Ublituximab

    Time frame: Up to Week 24

  4. Part A and B: Percentage of Participants with Treatment-emergent Anti-drug Antibodies (ADAs) to Ublituximab

    Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks

  5. Part A and B: Number of Gadolinium Enhancing (Gd-enhancing) T1 Lesions per Magnetic Resonance Imaging (MRI) Scan

    Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks

  6. Part A and B: Number of New and/or enlarging T2 Hyperintense Lesions (NELs) per MRI Scan

    Time frame: Part A: Up to Week 24; Part B: Up to 96 weeks

  7. Past A: Annualized Relapse Rate

    Time frame: Up to Week 24

  8. Part A and C: Change From Baseline in Expanded Disability Status Scale (EDSS) Score

    Time frame: Part A: Baseline, up to Week 24; Part C: Baseline, up to 168 weeks

  9. Part B: Pharmacokinetics (PK) Serum Concentration of Ublituximab

    Time frame: Up to Week 96

  10. Part B: Percentage of Participants with CD19+ B cell counts ≤10 cells/uL

    Time frame: Up to 96 weeks

  11. Part B: Annualized Relapse Rate ARR

    Time frame: Up to Week 96

  12. Part C: Time to Confirmed Disability Progression (CDP)

    Time frame: Up to Week 24

  13. Part C: Time to Confirmed Disability Improvement (CDI)

    Time frame: Up to Week 24

07

Study locations

5 of 6 sites recruiting
  • TG Therapeutics Investigational Trial Site
    Salt Lake City, Utah 84113, United States
    Recruiting
  • TG Therapeutics Investigational Trial Site
    Gdansk, 80-952, Poland
    Recruiting
  • TG Therapeutics Investigational Trial Site
    Poznan, 60-355, Poland
    Not yet recruiting
  • TG Therapeutics Investigational Trial Site
    Rzeszów, 35-301, Poland
    Recruiting
  • TG Therapeutics Investigational Trial Site
    Warsaw, 04-730, Poland
    Recruiting
  • TG Therapeutics Investigational Trial Site
    Bratislava, 83340, Slovakia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2030, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2025
First posted
Oct 23, 2025
StartActual
Jul 1, 2026
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jun 30, 2033
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first sites in Slovakia and United States
Show 3 added (1 United States, 1 Poland, 1 Slovakia)
  • TG Therapeutics Investigational Trial Site · Salt Lake City, United States
  • TG Therapeutics Investigational Trial Site · Rzeszów, Poland
  • TG Therapeutics Investigational Trial Site · Bratislava, Slovakia
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    3 sites added — first sites in Slovakia and United States
    Show 3 added (1 United States, 1 Poland, 1 Slovakia)
    • TG Therapeutics Investigational Trial Site · Salt Lake City, United States
    • TG Therapeutics Investigational Trial Site · Rzeszów, Poland
    • TG Therapeutics Investigational Trial Site · Bratislava, Slovakia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07220252
Responsible party
Sponsor
First posted
Oct 23, 2025
Start date
Jul 1, 2026
Primary completion
Jan 1, 2030 (estimated)
Completion
Jun 30, 2033 (estimated)
Last update
Oct 29, 2026

Study contacts

TG Therapeutics Clinical Support Team
Contact
clinicalsupport@tgtxinc.com
1-877-575-8489

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ublituximab · Fingolimod

Start the discussion